Beijietai
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Beijietai - overview
Established
2024
Location
Wuxi, Jiangsu, China
Primary Industry
Biotechnology
About
Established in 2024 and based in Wuxi, China, Beijietai operates as a biotech company that mainly research and develop biological products. It is a subsidiary of Staidson (Beijing) Biopharmaceuticals. In December 2024, the company raised CNY 200 million in venture funding from new investor Wuxi Guolian Industrial Investment Private Equity Fund Management. The company mainly develops biological drugs.
The products under development include STSP-0601, STSA-1301, and STSA-1503. STSA-1301 is for the indication of primary immune thrombocytopenia (ITP). The company generates revenue by developing biological drugs such as STSP-0601, STSA-1301, and STSA-1503.
Current Investors
Wuxi Guolian Industrial Investment Private Equity Fund Management
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Verticals
Manufacturing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.